News
05-26-2011, 09:11 PM
Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.
More... (http://www.news-medical.net/news/20110527/Tigris-Pharmaceuticals-begins-enrollment-in-AFP-464-Phase-2-trial-in-ER-positive-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20110527/Tigris-Pharmaceuticals-begins-enrollment-in-AFP-464-Phase-2-trial-in-ER-positive-breast-cancer.aspx)